Johnson & Johnson stock holds above $268 after FDA win
Published on 08/31/2026 at 07:16 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Johnson & Johnson Inc. (US4781601046) stock held above the $268 level after the U.S. FDA approved IMAAVY for warm autoimmune hemolytic anemia on August 24, 2026, a fresh catalyst that adds another growth asset to the portfolio. Recent market data put the shares at $268.30, with a market cap of $646.58 billion and a 52-week range of $173.33 to $276.47.
Approval adds a new rare-disease lever
The approval matters because IMAAVY is the first-ever treatment for warm autoimmune hemolytic anemia, and the supporting Phase 2/3 data showed a durable hemoglobin response with a mean increase of 1 g/dL at Week 1. That gives investors a concrete read-through on how Johnson & Johnson is trying to offset pressure from older franchises with newer immunology and rare-disease assets.
Product mix is the real story now. The company has been working to broaden growth beyond legacy blocks, and the new label expansion gives it a second recent execution point after China approved the oral psoriasis pill Icotyde in August 2026.
Valuation stays elevated
At the same time, the shares remain priced for quality. MarketBeat data showed a price-to-earnings ratio of 31.09, a price-to-earnings-growth ratio of 2.56 and a beta of 0.24, while the consensus target in that snapshot stood at $268.22, almost exactly where the stock opened on August 29, 2026.
The comparison is straightforward: the stock's 52-week high is $276.47, only $8.17 above the latest $268.30 open, which leaves the market valuing Johnson & Johnson close to its recent ceiling. The same data set also showed a 52-week low of $173.33, underscoring how far the shares have already recovered.
What the product line says
Imaavy, also known as nipocalimab-aahu, is the representative product in this move because it sits at the center of the company's latest regulatory win. The drug targets a rare blood disorder and gives the immunology franchise a clearer commercial story beyond broad portfolio maintenance.
Johnson & Johnson stock remains a large-cap healthcare name with a market cap above $646 billion, and the latest price action suggests investors are still paying up for defensive earnings power plus pipeline optionality. As of August 29, 2026, the shares were at $268.30 in regular trading.
Fact box
Company: Johnson & Johnson Inc.
ISIN: US4781601046
Ticker: JNJ
Exchange: NYSE
Price (as of August 29, 2026, 4:00 p.m. ET): $268.30 USD
Market cap: $646.58 billion (as of August 30, 2026)
Sector / Industry: Healthcare / Pharmaceuticals, Biotechnology & Life Sciences
Index membership: Dow Jones Industrial Average
More on Johnson & Johnson stock
The latest share price keeps Johnson & Johnson close to its 52-week peak, and the new FDA label gives the stock a fresh fundamental support point. For investors tracking the healthcare group, the combination of a $268.30 share price, a $646.58 billion market cap and a 31.09 P/E ratio is the key setup as August 2026 ends.
